Syphilis Testing Market Size, Top Share, Demand

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Syphilis Testing Market Size Analysis

Global Syphilis Testing Market Introduction
By Type
1. Introduction
  1. Type By Value
2. Primary Syphilis
  1. By Value
3. Secondary Syphilis
  1. By Value
By Test Type
1. Introduction
  1. Test Type By Value
2. Non-treponemal tests (RPR, VDRL)
  1. By Value
3. Treponemal immunoassays (TPPA, TPHA)
  1. By Value
4. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
  1. By Value
5. Rapid diagnostic tests (lateral flow immunoassays)
  1. By Value
6. Molecular tests (PCR/NAAT)
  1. By Value
7. Multiplex STI panels, including syphilis targets
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Molecular Diagnostics
  1. By Value
3. Immunoassay
  1. By Value
4. Others
  1. By Value
By Location of Testing
1. Introduction
  1. Location of Testing By Value
2. Laboratory Testing
  1. By Value
  2. Commercial/Private Labs
    1. Commercial/Private Labs By Value
  3. Public Health Labs
    1. Public Health Labs By Value
3. Point of Care Testing
  1. By Value

North America Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Primary Syphilis
  1. By Value
3. Secondary Syphilis
  1. By Value
By Test Type
1. Introduction
  1. Test Type By Value
2. Non-treponemal tests (RPR, VDRL)
  1. By Value
3. Treponemal immunoassays (TPPA, TPHA)
  1. By Value
4. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
  1. By Value
5. Rapid diagnostic tests (lateral flow immunoassays)
  1. By Value
6. Molecular tests (PCR/NAAT)
  1. By Value
7. Multiplex STI panels, including syphilis targets
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Molecular Diagnostics
  1. By Value
3. Immunoassay
  1. By Value
4. Others
  1. By Value
By Location of Testing
1. Introduction
  1. Location of Testing By Value
2. Laboratory Testing
  1. By Value
  2. Commercial/Private Labs
    1. Commercial/Private Labs By Value
  3. Public Health Labs
    1. Public Health Labs By Value
3. Point of Care Testing
  1. By Value
U.S.
1. By Type
  1. Introduction
    1. Type By Value
  2. Primary Syphilis
    1. By Value
  3. Secondary Syphilis
    1. By Value
2. By Test Type
  1. Introduction
    1. Test Type By Value
  2. Non-treponemal tests (RPR, VDRL)
    1. By Value
  3. Treponemal immunoassays (TPPA, TPHA)
    1. By Value
  4. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
    1. By Value
  5. Rapid diagnostic tests (lateral flow immunoassays)
    1. By Value
  6. Molecular tests (PCR/NAAT)
    1. By Value
  7. Multiplex STI panels, including syphilis targets
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Molecular Diagnostics
    1. By Value
  3. Immunoassay
    1. By Value
  4. Others
    1. By Value
4. By Location of Testing
  1. Introduction
    1. Location of Testing By Value
  2. Laboratory Testing
    1. By Value
    2. Commercial/Private Labs
      1. Commercial/Private Labs By Value
    3. Public Health Labs
      1. Public Health Labs By Value
  3. Point of Care Testing
    1. By Value
Canada

Europe Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Primary Syphilis
  1. By Value
3. Secondary Syphilis
  1. By Value
By Test Type
1. Introduction
  1. Test Type By Value
2. Non-treponemal tests (RPR, VDRL)
  1. By Value
3. Treponemal immunoassays (TPPA, TPHA)
  1. By Value
4. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
  1. By Value
5. Rapid diagnostic tests (lateral flow immunoassays)
  1. By Value
6. Molecular tests (PCR/NAAT)
  1. By Value
7. Multiplex STI panels, including syphilis targets
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Molecular Diagnostics
  1. By Value
3. Immunoassay
  1. By Value
4. Others
  1. By Value
By Location of Testing
1. Introduction
  1. Location of Testing By Value
2. Laboratory Testing
  1. By Value
  2. Commercial/Private Labs
    1. Commercial/Private Labs By Value
  3. Public Health Labs
    1. Public Health Labs By Value
3. Point of Care Testing
  1. By Value
U.K.
1. By Type
  1. Introduction
    1. Type By Value
  2. Primary Syphilis
    1. By Value
  3. Secondary Syphilis
    1. By Value
2. By Test Type
  1. Introduction
    1. Test Type By Value
  2. Non-treponemal tests (RPR, VDRL)
    1. By Value
  3. Treponemal immunoassays (TPPA, TPHA)
    1. By Value
  4. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
    1. By Value
  5. Rapid diagnostic tests (lateral flow immunoassays)
    1. By Value
  6. Molecular tests (PCR/NAAT)
    1. By Value
  7. Multiplex STI panels, including syphilis targets
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Molecular Diagnostics
    1. By Value
  3. Immunoassay
    1. By Value
  4. Others
    1. By Value
4. By Location of Testing
  1. Introduction
    1. Location of Testing By Value
  2. Laboratory Testing
    1. By Value
    2. Commercial/Private Labs
      1. Commercial/Private Labs By Value
    3. Public Health Labs
      1. Public Health Labs By Value
  3. Point of Care Testing
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Primary Syphilis
  1. By Value
3. Secondary Syphilis
  1. By Value
By Test Type
1. Introduction
  1. Test Type By Value
2. Non-treponemal tests (RPR, VDRL)
  1. By Value
3. Treponemal immunoassays (TPPA, TPHA)
  1. By Value
4. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
  1. By Value
5. Rapid diagnostic tests (lateral flow immunoassays)
  1. By Value
6. Molecular tests (PCR/NAAT)
  1. By Value
7. Multiplex STI panels, including syphilis targets
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Molecular Diagnostics
  1. By Value
3. Immunoassay
  1. By Value
4. Others
  1. By Value
By Location of Testing
1. Introduction
  1. Location of Testing By Value
2. Laboratory Testing
  1. By Value
  2. Commercial/Private Labs
    1. Commercial/Private Labs By Value
  3. Public Health Labs
    1. Public Health Labs By Value
3. Point of Care Testing
  1. By Value
China
1. By Type
  1. Introduction
    1. Type By Value
  2. Primary Syphilis
    1. By Value
  3. Secondary Syphilis
    1. By Value
2. By Test Type
  1. Introduction
    1. Test Type By Value
  2. Non-treponemal tests (RPR, VDRL)
    1. By Value
  3. Treponemal immunoassays (TPPA, TPHA)
    1. By Value
  4. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
    1. By Value
  5. Rapid diagnostic tests (lateral flow immunoassays)
    1. By Value
  6. Molecular tests (PCR/NAAT)
    1. By Value
  7. Multiplex STI panels, including syphilis targets
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Molecular Diagnostics
    1. By Value
  3. Immunoassay
    1. By Value
  4. Others
    1. By Value
4. By Location of Testing
  1. Introduction
    1. Location of Testing By Value
  2. Laboratory Testing
    1. By Value
    2. Commercial/Private Labs
      1. Commercial/Private Labs By Value
    3. Public Health Labs
      1. Public Health Labs By Value
  3. Point of Care Testing
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Primary Syphilis
  1. By Value
3. Secondary Syphilis
  1. By Value
By Test Type
1. Introduction
  1. Test Type By Value
2. Non-treponemal tests (RPR, VDRL)
  1. By Value
3. Treponemal immunoassays (TPPA, TPHA)
  1. By Value
4. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
  1. By Value
5. Rapid diagnostic tests (lateral flow immunoassays)
  1. By Value
6. Molecular tests (PCR/NAAT)
  1. By Value
7. Multiplex STI panels, including syphilis targets
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Molecular Diagnostics
  1. By Value
3. Immunoassay
  1. By Value
4. Others
  1. By Value
By Location of Testing
1. Introduction
  1. Location of Testing By Value
2. Laboratory Testing
  1. By Value
  2. Commercial/Private Labs
    1. Commercial/Private Labs By Value
  3. Public Health Labs
    1. Public Health Labs By Value
3. Point of Care Testing
  1. By Value
UAE
1. By Type
  1. Introduction
    1. Type By Value
  2. Primary Syphilis
    1. By Value
  3. Secondary Syphilis
    1. By Value
2. By Test Type
  1. Introduction
    1. Test Type By Value
  2. Non-treponemal tests (RPR, VDRL)
    1. By Value
  3. Treponemal immunoassays (TPPA, TPHA)
    1. By Value
  4. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
    1. By Value
  5. Rapid diagnostic tests (lateral flow immunoassays)
    1. By Value
  6. Molecular tests (PCR/NAAT)
    1. By Value
  7. Multiplex STI panels, including syphilis targets
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Molecular Diagnostics
    1. By Value
  3. Immunoassay
    1. By Value
  4. Others
    1. By Value
4. By Location of Testing
  1. Introduction
    1. Location of Testing By Value
  2. Laboratory Testing
    1. By Value
    2. Commercial/Private Labs
      1. Commercial/Private Labs By Value
    3. Public Health Labs
      1. Public Health Labs By Value
  3. Point of Care Testing
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Primary Syphilis
  1. By Value
3. Secondary Syphilis
  1. By Value
By Test Type
1. Introduction
  1. Test Type By Value
2. Non-treponemal tests (RPR, VDRL)
  1. By Value
3. Treponemal immunoassays (TPPA, TPHA)
  1. By Value
4. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
  1. By Value
5. Rapid diagnostic tests (lateral flow immunoassays)
  1. By Value
6. Molecular tests (PCR/NAAT)
  1. By Value
7. Multiplex STI panels, including syphilis targets
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Molecular Diagnostics
  1. By Value
3. Immunoassay
  1. By Value
4. Others
  1. By Value
By Location of Testing
1. Introduction
  1. Location of Testing By Value
2. Laboratory Testing
  1. By Value
  2. Commercial/Private Labs
    1. Commercial/Private Labs By Value
  3. Public Health Labs
    1. Public Health Labs By Value
3. Point of Care Testing
  1. By Value
Brazil
1. By Type
  1. Introduction
    1. Type By Value
  2. Primary Syphilis
    1. By Value
  3. Secondary Syphilis
    1. By Value
2. By Test Type
  1. Introduction
    1. Test Type By Value
  2. Non-treponemal tests (RPR, VDRL)
    1. By Value
  3. Treponemal immunoassays (TPPA, TPHA)
    1. By Value
  4. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
    1. By Value
  5. Rapid diagnostic tests (lateral flow immunoassays)
    1. By Value
  6. Molecular tests (PCR/NAAT)
    1. By Value
  7. Multiplex STI panels, including syphilis targets
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Molecular Diagnostics
    1. By Value
  3. Immunoassay
    1. By Value
  4. Others
    1. By Value
4. By Location of Testing
  1. Introduction
    1. Location of Testing By Value
  2. Laboratory Testing
    1. By Value
    2. Commercial/Private Labs
      1. Commercial/Private Labs By Value
    3. Public Health Labs
      1. Public Health Labs By Value
  3. Point of Care Testing
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Syphilis Testing Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Hoffmann-La Roche Ltd
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Abbott
BD
Siemens Healthineers AG
BIOMÉRIEUX
Hologic, Inc.
Cepheid
Bio-Rad Laboratories, Inc.
Thermo Fisher Scientific Inc
QuidelOrtho Corporation
Trinity Biotech
SD Biosensor, INC
ARLINGTON SCIENTIFIC
DiaSorin S.p.A.
Beckman Coulter, Inc.
bioLytical Laboratories Inc.
Others

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment